Skip to main content

Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology.

Publication ,  Journal Article
Radich, JP; Deininger, M; Abboud, CN; Altman, JK; Berman, E; Bhatia, R; Bhatnagar, B; Curtin, P; DeAngelo, DJ; Gotlib, J; Hobbs, G; Jagasia, M ...
Published in: J Natl Compr Canc Netw
September 2018

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor (TKI) therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML (CP-CML). The selection TKI therapy should be based on the risk score, toxicity profile of TKI, patient's age, ability to tolerate therapy, and the presence of comorbid conditions. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CP-CML.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

September 2018

Volume

16

Issue

9

Start / End Page

1108 / 1135

Location

United States

Related Subject Headings

  • United States
  • Societies, Medical
  • Risk Assessment
  • Real-Time Polymerase Chain Reaction
  • Protein Kinase Inhibitors
  • Progression-Free Survival
  • Prognosis
  • Philadelphia Chromosome
  • Patient Selection
  • Oncology & Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Radich, J. P., Deininger, M., Abboud, C. N., Altman, J. K., Berman, E., Bhatia, R., … Sundar, H. (2018). Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 16(9), 1108–1135. https://doi.org/10.6004/jnccn.2018.0071
Radich, Jerald P., Michael Deininger, Camille N. Abboud, Jessica K. Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, et al. “Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw 16, no. 9 (September 2018): 1108–35. https://doi.org/10.6004/jnccn.2018.0071.
Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, et al. Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Sep;16(9):1108–35.
Radich, Jerald P., et al. “Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw, vol. 16, no. 9, Sept. 2018, pp. 1108–35. Pubmed, doi:10.6004/jnccn.2018.0071.
Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hobbs G, Jagasia M, Kantarjian HM, Maness L, Metheny L, Moore JO, Pallera A, Pancari P, Patnaik M, Purev E, Rose MG, Shah NP, Smith BD, Snyder DS, Sweet KL, Talpaz M, Thompson J, Yang DT, Gregory KM, Sundar H. Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Sep;16(9):1108–1135.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

September 2018

Volume

16

Issue

9

Start / End Page

1108 / 1135

Location

United States

Related Subject Headings

  • United States
  • Societies, Medical
  • Risk Assessment
  • Real-Time Polymerase Chain Reaction
  • Protein Kinase Inhibitors
  • Progression-Free Survival
  • Prognosis
  • Philadelphia Chromosome
  • Patient Selection
  • Oncology & Carcinogenesis